

PRODUCT INFORMATION



TNFSF8/CD30 Ligand Extracellular Domain (human, recombinant)


Item No. 40213

Overview and Properties


Synonyms:	CD153, CD30L, TNFSF8, Tumor Necrosis Factor Ligand Superfamily Member 8
Source:	Active recombinant N-terminal human IgG1 Fc-tagged CD30L expressed in HEK293 cells
Amino Acids:	63-234
Uniprot No.:	P32971
Molecular Weight:	47.8 kDa
Storage:	-80°C (as supplied)
Stability:	≥1 year
Purity:	≥95% estimated by SDS-PAGE
Supplied in:	Lyophilized from sterile PBS, pH 7.4
Endotoxin Testing:	<1.0 EU/μg, determined by the LAL endotoxin assay
Bioactivity:	See figures for details

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Images



SDS-PAGE Analysis of TNFSF8/CD30 Ligand Extracellular Domain. This protein has a calculated molecular weight of 47.8 kDa.



Measured by its binding ability in a functional ELISA. Immobilized TNFSF8/CD30 Ligand Extracellular Domain (human, recombinant) (Item No. 40213) at 2 μg/ml (100 μl/well) can bind human CD30/TNFRSF8-Fch the EC₅₀ of TNFSF8/CD30 Ligand Extracellular Domain (human, recombinant) (Item No. 40213) is 15-60 ng/ml.

WARNING
THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA
This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY
Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 11/16/2023

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM

PRODUCT INFORMATION



Description

CD30 ligand (CD30L), also known as TNF superfamily member 8 (TNFSF8), is a single-pass type II membrane glycoprotein and member of the TNF and TNF receptor cytokine superfamily.¹ It is composed of a cytoplasmic, transmembrane, and extracellular domain and forms non-covalent homotrimers.^{1,2} CD30L is expressed on activated T cells, as well as on B cells, macrophages, and granulocytes.^{1,3} It binds to CD30, inducing NF- κ B- or ERK/MAPK-dependent downstream signaling that is involved in cell proliferation, cell activation, and the T cell-dependent immune response in a cell type- and cell activation status-dependent manner.^{1,3-6} CD30L can bind to both membrane-associated and soluble CD30, but binding to soluble CD30 prevents its binding to the membrane-bound form.¹ CD30L is found on cells of various hematological cancers, including Hodgkin lymphoma and anaplastic large cell lymphoma, and expression of *TNFSF8* is increased in leukocytes in autoimmune and inflammatory diseases, such as systemic lupus erythematosus (SLE) and asthma.⁴ Cayman's TNFSF8/CD30 Ligand Extracellular Domain (human, recombinant; Fc-tagged) protein can be used for binding assays. This protein is a disulfide-linked homodimer. The reduced monomer, composed of CD30L (amino acids 63-234) fused to human IgG1 Fc at its N-terminus, consists of 429 amino acids, has a calculated molecular weight of 47.8 kDa, and a predicted N-terminus of Arg23 after signal peptide cleavage. As a result of glycosylation, the monomer migrates at approximately 60-65 kDa by SDS-PAGE under reducing conditions.

References

1. Hargreaves, P.G. and Al-Shamkhani, A. Soluble CD30 binds to CD153 with high affinity and blocks transmembrane signaling by CD30. *Eur. J. Immunol.* **32**(1), 163-173 (2002).
2. Horie, R. and Watanabe, T. CD30: Expression and function in health and disease. *Semin. Immunol.* **10**(6), 457-470 (1998).
3. Blazar, B.R., Levy, R.B., Mak, T.W., *et al.* CD30/CD30 ligand (CD153) interaction regulates CD4⁺ T cell-mediated graft-versus-host disease. *J. Immunol.* **173**(5), 2933-2941 (2004).
4. Oflazoglu, E., Grewal, I.S., and Gerber, H. Targeting CD30/CD30L in oncology and autoimmune and inflammatory diseases. *Adv. Exp. Med. Biol.* **647**, 174-185 (2009).
5. Gottesman, S.R.S. CD30: Receptor, marker, target. *Pathol. Lab. Med. Int.* **8**(1), 27-36 (2016).
6. van de Weyden, C.A., Pileri, S.A., Feldman, A.L., *et al.* Understanding CD30 biology and therapeutic targeting: A historical perspective providing insight into future directions. *Blood Cancer J.* **7**(9), e603 (2017).

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM